S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   172.97 (+0.33%)
MSFT   317.95 (+1.46%)
META   304.45 (+1.17%)
GOOGL   134.65 (+1.68%)
AMZN   126.59 (+1.50%)
TSLA   257.67 (+4.52%)
NVDA   438.75 (+0.82%)
NIO   8.75 (+1.63%)
BABA   84.02 (-0.62%)
AMD   102.43 (+2.35%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.92 (+0.13%)
CGC   0.75 (+9.50%)
GE   108.78 (+0.95%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.37 (-1.56%)
PYPL   58.10 (+1.40%)
NFLX   376.18 (-0.15%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   172.97 (+0.33%)
MSFT   317.95 (+1.46%)
META   304.45 (+1.17%)
GOOGL   134.65 (+1.68%)
AMZN   126.59 (+1.50%)
TSLA   257.67 (+4.52%)
NVDA   438.75 (+0.82%)
NIO   8.75 (+1.63%)
BABA   84.02 (-0.62%)
AMD   102.43 (+2.35%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.92 (+0.13%)
CGC   0.75 (+9.50%)
GE   108.78 (+0.95%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.37 (-1.56%)
PYPL   58.10 (+1.40%)
NFLX   376.18 (-0.15%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   172.97 (+0.33%)
MSFT   317.95 (+1.46%)
META   304.45 (+1.17%)
GOOGL   134.65 (+1.68%)
AMZN   126.59 (+1.50%)
TSLA   257.67 (+4.52%)
NVDA   438.75 (+0.82%)
NIO   8.75 (+1.63%)
BABA   84.02 (-0.62%)
AMD   102.43 (+2.35%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.92 (+0.13%)
CGC   0.75 (+9.50%)
GE   108.78 (+0.95%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.37 (-1.56%)
PYPL   58.10 (+1.40%)
NFLX   376.18 (-0.15%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   172.97 (+0.33%)
MSFT   317.95 (+1.46%)
META   304.45 (+1.17%)
GOOGL   134.65 (+1.68%)
AMZN   126.59 (+1.50%)
TSLA   257.67 (+4.52%)
NVDA   438.75 (+0.82%)
NIO   8.75 (+1.63%)
BABA   84.02 (-0.62%)
AMD   102.43 (+2.35%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.92 (+0.13%)
CGC   0.75 (+9.50%)
GE   108.78 (+0.95%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.37 (-1.56%)
PYPL   58.10 (+1.40%)
NFLX   376.18 (-0.15%)
LON:OXB

Oxford Biomedica (OXB) Share Forecast, Price & News

GBX 300
-7.00 (-2.28%)
(As of 04:45 PM ET)
Compare
Today's Range
297
308
50-Day Range
240
451.50
52-Week Range
236.50
575
Volume
113,653 shs
Average Volume
122,098 shs
Market Capitalization
£289.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 605

Oxford Biomedica MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
103.0% Upside
GBX 605 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
£10.19 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars


OXB stock logo

About Oxford Biomedica (LON:OXB) Stock

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Price History

OXB Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Oxford Biomedica Posts FY Loss
CGT CDMO Market Share and Forecast till 2030
See More Headlines
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
894
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 605
High Stock Price Forecast
GBX 1,010
Low Stock Price Forecast
GBX 310
Forecasted Upside/Downside
+103.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
£-61,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£119.02 million
Cash Flow
GBX 99.12 per share
Book Value
GBX 178 per share

Miscellaneous

Free Float
N/A
Market Cap
£287.87 million
Optionable
Not Optionable
Beta
1.03
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Stuart Paynter (Age 49)
    CFO, Company Sec. & Director
    Comp: $832k
  • Dr. Frank Mathias (Age 61)
    CEO & Director
  • Mr. Nick Page
    Chief Operations Officer
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer & Chief of Staff
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    Gen. Counsel
  • Ms. Lisa James
    Chief People Officer
  • Ms. Sarah Macleod
    Head of Communications













OXB Stock - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings
or view top-rated stocks.

What is Oxford Biomedica's stock price forecast for 2023?

3 analysts have issued 1 year target prices for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 310 to GBX 1,010. On average, they expect the company's stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts price targets for OXB
or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 at the beginning of the year. Since then, OXB shares have decreased by 32.7% and is now trading at GBX 298.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 298.

How much money does Oxford Biomedica make?

Oxford Biomedica (LON:OXB) has a market capitalization of £287.87 million and generates £119.02 million in revenue each year. The biopharmaceutical company earns £-61,630,000.00 in net income (profit) each year or GBX (0.66) on an earnings per share basis.

How many employees does Oxford Biomedica have?

The company employs 894 workers across the globe.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page (LON:OXB) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -